000 04384nam a22005175i 4500
001 978-88-470-0358-3
003 DE-He213
005 20161121230602.0
007 cr nn 008mamaa
008 100301s2005 it | s |||| 0|eng d
020 _a9788847003583
_9978-88-470-0358-3
024 7 _a10.1007/b138963
_2doi
050 4 _aRC681-688.2
072 7 _aMJD
_2bicssc
072 7 _aMED010000
_2bisacsh
082 0 4 _a616.12
_223
245 1 0 _aCardiovascular Disease in AIDS
_h[electronic resource] /
_cedited by Giuseppe Barbaro, Franck Boccara.
264 1 _aMilano :
_bSpringer Milan,
_c2005.
300 _aX, 169 p. 90 illus.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aEvolution and Pathogenesis of the Involvement of the Cardiovascular System in HIV Infection -- Pathogenesis of HAART-Associated Metabolic Syndrome -- Pathology of Cardiac Complications in HIV Infection -- Pathology of Peripheral and Coronary Vessels in AIDS Patients -- Coronary Heart Disease in HIV-Infected Patients: Epidemiology -- Coronary Artery Disease in HIV-Infected Patients: Clinical Presentation, Pathophysiology, Prognosis, Prevention, and Treatment -- Cerebrovascular Disease in HIV-Infected Patients -- Peripheral Arterial Disease in HIV-Infected Patients: Atherosclerosis and Vasculitic Syndromes -- HIV-Associated Pulmonary Hypertension -- Coagulative Disorders in HIV-Infected Patients -- Cardiovascular Complications in HIV-Infected Children -- Cardiac Surgery and the Human Immunodeficiency Virus -- Cardiological Emergencies in HIV-Infected Patients -- Guidelines for the Prevention of Cardiovascular Risk in HIV-Infected Patients Treated with Antiretroviral Drugs.
520 _aThe introduction of highly active antiretroviral therapy (HAART) has significantly improved the clinical outcome of HIV disease with increased survival rates. However, the introduction of HAART has generated a contrast in the cardiac manifestations of AIDS. In developed countries, we observed an approximate 30% reduction in the prevalence of HIV-associated cardiomyopathy, possibly related to a reduction of opportunistic infections and myocarditis. In developing countries, however, where the availablity of HAART is limited and the pathogenic impact of nutritional factors is significant, we observed an approximate 32% increase in the prevalence of HIV-associated cardiomyopathy and a related high mortality rate from congestive heart failure. Also, some HAART regimens in developed countries, especially those including protease inhibitors, may cause a iatrogenic metabolic syndrome (HIV-lipodystrophy syndrome) that is associated with an increased risk of cardiovascular disease. At the same time, the relapse of some oppurtunistic infections, with possible myocardial involvement, in HIV-infected patients receiving HAART, in the context of the recently described immune reconstitution inflammatory syndrome, yielded an intriguing and complex profile of this double face of cardiology in AIDS in the HAART era. In this new edition of Cardiovascular Disease in AIDS new insights coming from basic and clinical research in the field of HIV-associated cardiovascular disease and antiretroviral therapy are reported, along with the clinical guidelines for a careful stratification of the cardiovascular risk and cardiovascular monitoring of HIV-infected patients receiving HAART. The authors offer a wide overview of the topic for specialists in cardiology and infectious diseases involved in the clinical management of HIV-infected patients.
650 0 _aMedicine.
650 0 _aInternal medicine.
650 0 _aCardiology.
650 0 _aInfectious diseases.
650 0 _aNeurology.
650 0 _aCardiac surgery.
650 1 4 _aMedicine & Public Health.
650 2 4 _aCardiology.
650 2 4 _aInternal Medicine.
650 2 4 _aInfectious Diseases.
650 2 4 _aNeurology.
650 2 4 _aCardiac Surgery.
700 1 _aBarbaro, Giuseppe.
_eeditor.
700 1 _aBoccara, Franck.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9788847003095
856 4 0 _uhttp://dx.doi.org/10.1007/b138963
912 _aZDB-2-SME
950 _aMedicine (Springer-11650)
999 _c500951
_d500951